How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,081 results for

Thromboembolic Disease in Pregnancy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

and rivaroxaban for the treatment of VTE. Condition or disease Intervention/treatment Phase Venous Thromboembolism Drug: Apixaban Drug: Rivaroxaban Phase 4 Detailed Description: VTE is the third leading cause of mortality by cardiovascular disease. Standard treatment for acute VTE uses a combination of parenteral Low-Molecular-Weight Heparin (LMWH) and oral vitamin K antagonists (VKA) for 3 months, and carries significant bleeding risk. The major and/or clinically-relevant non-major bleeding (CRNMB) event (...) ) pregnant (note below) or breastfeeding (Note: as reported by the patient or a pregnancy test will be ordered at the discretion of the treating physician for women of childbearing potential as per standard of care) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT

2017 Clinical Trials

162. Distribution of Risk Factors for Venous Thromboembolism in Blood Donors

in patients with VTE. Condition or disease Intervention/treatment Venous Thromboembolism Risk Factor, Cardiovascular Blood Type Behavioral: no intervention Detailed Description: Venous thromboembolism, defined by deep vein thrombosis (DVT) and / or pulmonary embolism (PE), occurs with an incidence of about 1 per 1000 per year in adult populations. Rates are slightly higher in men than women. About two-thirds of the episodes are manifested as DVT and one third as PE with or without DVT. The main (...) of Bari Information provided by (Responsible Party): Elvira Grandone, MD, Head of Unit, Casa Sollievo della Sofferenza IRCCS Study Details Study Description Go to Brief Summary: Venous thromboembolism occurs with an incidence of about 1 per 1000 per year in adults . The main consequences are death, recurrence, post-thrombotic syndrome and major bleeding due to anticoagulation. Mortality rates are lower among patients with idiopathic venous thrombosis and higher among those in whom thrombosis occurs

2017 Clinical Trials

163. Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism

of bleeding or VTE recurrence. Condition or disease Intervention/treatment Venous Thromboembolism Drug: Apixaban Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 850 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Monotherapy Anticoagulation To Expedite Home Treatment of Venous Actual Study Start Date : August 4, 2017 Estimated Primary Completion Date : December 31, 2020 Estimated Study Completion Date : December (...) or social reasons to admit Creatinine clearance >30mL/min Not pregnant, severe liver disease or heparin induced thrombocytopenia OR B. The physician opinion that a patients' overall social and medical situation is favorable for home treatment and the patient has a zero score on the simplified pulmonary embolism severity index (sPESI). All of the following must true: Age < 81 years No history of cancer No history of heart failure or chronic lung disease Pulse < 110 beats/min SBP > 99 mm Hg O2 sat >89

2017 Clinical Trials

164. Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer

Posted : October 26, 2018 See Sponsor: Fadoi Foundation, Italy Collaborator: University of Perugia, Italy Information provided by (Responsible Party): Fadoi Foundation, Italy Study Details Study Description Go to Brief Summary: Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study Condition or disease Intervention/treatment Phase Venous Thromboembolism Drug: Apixaban Drug: Dalteparin Phase 3 Study Design Go (...) participation in other pharmaco therapeutic program with an experimental therapy that is known to effect the coagulation system; childbearing potential without proper contraceptive measures, pregnancy, or breast feeding; any condition that as judged by the Investigator would place the subject at increased risk of harm if he/she participated in the study. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study

2017 Clinical Trials

165. Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)

lung cancer and elevated D-dimer. Condition or disease Intervention/treatment Phase Venous Thromboembolism Lung Neoplasm Drug: Tinzaparin Sodium Phase 3 Detailed Description: Adult patients aged ≥ 18 years with stage IV lung cancer and elevated D-dimer will be randomized to the experimental or control group.Patients in the control group will receive usual care, patients in the experimental group will receive subcutaneous tinzaparin once daily for six months. Follow-up visit will take place (...) table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Assistance Publique - Hôpitaux de Paris: Low-molecular-weight Heparin Tinzaparin Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Venous Thromboembolism Lung Neoplasms Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases

2017 Clinical Trials

166. Incidence of Venous Thromboembolism in Patients Undergoing Major Esophageal Resection

Update Posted : December 20, 2018 See Sponsor: McMaster University Information provided by (Responsible Party): McMaster University Study Details Study Description Go to Brief Summary: The purpose of this study is to determine the incidence of post-operative venous thromboembolism (VTE) in patients undergoing major esophageal resection for malignancy. Condition or disease Venous Thromboembolism Thoracic Surgery Esophageal Cancer Detailed Description: Venous Thromboembolism (VTE) is a common post (...) therapies. Patients must receive VTE prophylaxis as per local institutional guidelines Patients must be competent to understand and sign consent documents. Exclusion Criteria: All patients with known allergic or anaphylactic reaction to contrast dye, heparin, or low molecular weight heparin (LMWH). Patients must not be under current anticoagulation for venous thromboembolism or other medical conditions. Patients must not have known renal impairment, defined as creatinine clearance value of less than

2017 Clinical Trials

167. Non-Contrast 4DCT to Detect Pulmonary Thromboembolic Events

participants will be enrolled under the same criteria and study procedures as Cohort 1. The participants in Cohort 2 will have the addition of Bilevel Positive Airway Pressure (BiPAP) during the 4DCT imaging. Cohort 3: 124 participants will be enrolled. Study procedure will be 4DCT only. Participants must be having or have had a CTA to rule out PE. This cohort of the study will be using 4DCT to compare negative CTA to positive CTA findings. Condition or disease Intervention/treatment Phase Pulmonary (...) a U.S. FDA-regulated Device Product: Yes Device Product Not Approved or Cleared by U.S. FDA: No Pediatric Postmarket Surveillance of a Device Product: No Product Manufactured in and Exported from the U.S.: No Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Embolism Pulmonary Embolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases

2017 Clinical Trials

168. Thrombosis Outcomes in Pediatric Venous Thromboembolism

biomarkers in children that develop poor VTE outcomes (such as recurrence, postthrombotic syndrome and post PE impairment ) after an initial VTE with those that do not develop such outcomes. Condition or disease Venous Thromboembolism Detailed Description: All newly diagnosed patients with a first radiologically confirmed thrombotic event (any site) diagnosed at Children's Medical Center, Dallas will be followed prospectively with global coagulation assessment over a 24-month period, and monitored (...) malignancy Pregnancy or immediate post-partum period (12 weeks after delivery) Sickle cell disease Known bleeding disorder Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03068923 Contacts Layout table for location contacts Contact: Kendra Malone, MPH

2017 Clinical Trials

169. Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism

: Duke University Collaborator: Patient-Centered Outcomes Research Institute Information provided by (Responsible Party): Duke University Study Details Study Description Go to Brief Summary: Comparison of Oral anticoagulants (warfarin, apixaban and rivaroxaban) for extended VEnous Thromboembolism. Condition or disease Intervention/treatment Phase Venous Thromboembolism Drug: Warfarin Drug: Apixaban 2.5 MG Drug: Rivaroxaban 10 MG Phase 4 Detailed Description: Determine if apixaban is superior (...) twice daily, would not be appropriate therapy) A clinical indication for a specific anticoagulant regimen (e.g., warfarin with a target INR of 2-3 is recommended for patients with 'triple-positive' antiphospholipid syndrome). Life expectancy < 3 months Currently pregnant or breast feeding Unable / unwilling to pay for one (or more) of the treatment options Active Cancer defined as: Diagnosed with cancer within the past 6 months; or Recurrent, regionally advanced or metastatic disease; Currently

2017 Clinical Trials

170. Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure

thromboembolism in first-degree relatives of women who did not have venous thromboembolism during a similar hormonal exposure. The primary objective is to determine the association between the presence or the absence of VTE in young women during hormonal exposure and the presence or the absence of a previous episode of VTE in their first-degree relatives. Secondary objective is to determine the impact of associated inherited thrombophilia on the risk of VTE in first-degree relatives. Condition or disease (...) See Sponsor: University Hospital, Brest Information provided by (Responsible Party): University Hospital, Brest Study Details Study Description Go to Brief Summary: Young women have an increased risk of venous thromboembolism (VTE) during hormonale exposure (estrogen-containing pill or pregnancy). In order to detect women at higher risk of VTE during hormonal exposure, thrombophilia testing is often performed in order to adapt contraception methods and/or to increases thromboprophylaxy during

2017 Clinical Trials

171. Thromboembolism and in-vitro fertilization -NDASH- a systematic review. Full Text available with Trip Pro

studies, three case series, and three reviews of case series) were identified. The antepartum risk of venous thromboembolism (VTE) after IVF is doubled (odds ratio 2.18, 95% CI 1.63-2.92), compared with the background pregnant population. This is due to a 5- to 10-fold increased risk during the first trimester in IVF pregnancies, in turn related to a very high risk of VTE after ovarian hyperstimulation syndrome (OHSS), i.e. up to a 100-fold increase, or an absolute risk of 1.7%. The interval from (...) embryo transfer to VTE was 3-112 days and the interval from embryo transfer to arterial thromboembolism was 3-28 days. No robust study on thromboprophylaxis was found.The antepartum risk of VTE after IVF is doubled, compared with the background pregnant population, and is in turn related to a very high risk of VTE after OHSS in the first trimester. We recommend that IVF patients with OHSS be prescribed low-molecular-weight heparin during the first trimester, whereas other IVF patients should be given

2017 Acta Obstetricia et Gynecologica Scandinavica

172. Incidence and risk factors of venous thromboembolism during postpartum-period: a population-based cohort-study. Full Text available with Trip Pro

, primiparity, cesarean section, cardiac/renal diseases, and varicose veins were associated with an increased risk for postpartum venous thromboembolic events. The risk remained elevated for 180 days in women with thrombophilia, cesarean section, multiple pregnancy, varicose veins, and cardiac disease.The risk of venous thromboembolic events remained elevated compared with that of the nonpregnant women after the usually defined postpartum period (6 weeks). The results might assist in selecting women in need (...) , declining to two-fold immediately after that. Almost half of the venous thromboembolic events occurred between 43 and 180 days postpartum. The incidence of venous thromboembolic events was four-fold compared with that of nonpregnant women. Three venous thromboembolic events-related deaths occurred. Older age, higher body mass index, thrombophilia, multiple pregnancy, gestational diabetes, anemia, chorioamnionitis, threatening premature birth, in vitro fertilization with ovarian hyperstimulation

2017 Acta Obstetricia et Gynecologica Scandinavica

173. Hepatic infarction in a pregnant woman with antiphospholipid syndrome and triple antibody positivity: A case report focusing on catastrophic antiphospholipid syndrome Full Text available with Trip Pro

Hepatic infarction in a pregnant woman with antiphospholipid syndrome and triple antibody positivity: A case report focusing on catastrophic antiphospholipid syndrome Pregnant women with antiphospholipid syndrome (APS) carry a high risk of arterial or venous thrombosis. Such thrombotic conditions occur more frequently in patients with triple positivity to antiphospholipid antibodies or with high antibody titers. Hepatic infarction is a rare complication in pregnant women with APS (...) , and it sometimes mimics HELLP syndrome. This report describes a preeclamptic pregnant woman with APS who had high titers of three antiphospholipid antibodies. She experienced severe epigastric pain with elevated liver enzymes; in addition, she had tachycardia and tachypnea. The clinical findings suggested hepatic infarction and pulmonary thromboembolism, a partial manifestation of catastrophic APS. Therefore, she underwent emergent cesarean section at 25+2 weeks of gestation. After the delivery, her laboratory

2016 Obstetrics & gynecology science

174. Weight management before, during and after pregnancy

with, or who are receiving treatment for, an existing condition such as type 1 or type 2 diabetes food safety advice. The guidance is for NHS and other commissioners, managers and professionals who have a direct or indirect role in, and responsibility for, women who are pregnant or who are planning a pregnancy and mothers who have had a baby in the last 2 years. This includes those working in local authorities, education and the wider public, private, voluntary and community sectors. It is particularly (...) folic acid supplements. This includes professionals working in pre-conception clinics, fertility clinics, sexual and reproductive health services and children's centres. Weight management before, during and after pregnancy (PH27) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 11 of 59Recommendation 2 Pregnant women Conte Context xt If a pregnant woman is obese this will have a greater influence on her health

2010 National Institute for Health and Clinical Excellence - Clinical Guidelines

175. Risk of Pulmonary and Venous Thromboembolism in Pregnancies After in Vitro Fertilization

concerning pulmonary embolism (PE). The aim is to estimate and compare the risk of both PE and VTE during the the different phases of pregnancy after IVF to that in age and period matched control women. The investigators will use the Swedish National Health Registers to estimate the risk. Condition or disease Pulmonary Embolism Venous Thromboembolism Detailed Description: Background: Occurrence of venous thromboembolism (VTE) during IVF pregnancies has been reported in numerous case reports and in two (...) Posted: February 2, 2012 Last Verified: January 2012 Keywords provided by Professor Peter Henriksson, Danderyd Hospital: Assisted Reproductive Techniques Pregnancy Pulmonary Embolism Venous Thromboembolism Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Embolism Venous Thromboembolism Pulmonary Embolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases

2012 Clinical Trials

176. Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD Full Text available with Trip Pro

for the management of patients with diabetes and acute or chronic coronary syndromes 33 Recommendations for coronary revascularization in patients with diabetes 35 Recommendations for the type of revascularization in patients with diabetes with stable coronary artery disease, suitable coronary anatomy for both procedures, and low predicted surgical mortality 36 Recommendations for the treatment of heart failure in patients with diabetes 39 Recommendations for the treatment of patients with type 2 diabetes (...) plasma glucose ABI Ankle–brachial index ABPM Ambulatory blood pressure monitoring ACCORD Action to Control Cardiovascular Risk in Diabetes ACE Acarbose Cardiovascular Evaluation ACEI Angiotensin-converting enzyme inhibitor ACS Acute coronary syndrome ADA American Diabetes Association ADVANCE Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation ADDITION Anglo-Danish-Dutch Study of Intensive Treatment In People with Screen Detected Diabetes in Primary Care ADOPT

2019 European Society of Cardiology

177. Disorders of the Hepatic and Mesenteric Circulation Full Text available with Trip Pro

Abstract Disorders of the mesenteric, portal, and hepatic veins and mesenteric and hepatic arteries have important clinical consequences and may lead to acute liver failure, chronic liver disease, noncirrhotic portal hypertension, cirrhosis, and hepatocellular carcinoma. Although literature in the field of vascular liver disorders is scant, these disorders are common in clinical practice, and general practitioners, gastroenterologists, and hepatologists may benefit from expert guidance (...) and recommendations for management of these conditions. These guidelines represent the official practice recommendations of the American College of Gastroenterology. Key concept statements based on author expert opinion and review of literature and specific recommendations based on PICO/GRADE analysis have been developed to aid in the management of vascular liver disorders. These recommendations and guidelines should be tailored to individual patients and circumstances in routine clinical practice. INTRODUCTION

2020 American College of Gastroenterology

178. Antiphospholipid syndrome

Antiphospholipid syndrome Antiphospholipid syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Antiphospholipid syndrome Last reviewed: February 2019 Last updated: March 2018 Summary Persistently elevated antiphospholipid antibodies associated with thromboses and pregnancy-related morbidity are key diagnostic criteria. Predisposes to arterial and microvascular thrombosis, as well as venous thromboembolism (...) , and can affect any vessel in the body. Main treatment goals are management of acute thrombosis and prevention of thrombosis recurrence and pregnancy morbidity. Consideration should also be given to the presence of co-existent autoimmune disease in patients with antiphospholipid syndrome. Catastrophic disease, which presents as multiorgan failure, occurs in <1% of patients. High index of suspicion for antiphospholipid syndrome in any young patient (<50 years) presenting with arterial thrombosis in any

2018 BMJ Best Practice

179. Thromboembolism in pregnancy. Full Text available with Trip Pro

Thromboembolism in pregnancy. 476455 1979 11 29 2013 11 21 0007-1447 2 6185 1979 Aug 04 British medical journal Br Med J Thromboembolism in pregnancy. 333 Orme M L ML Serlin M J MJ Breckenridge A A eng Letter England Br Med J 0372673 0007-1447 5Q7ZVV76EI Warfarin AIM IM Breast Feeding Female Humans Pregnancy Puerperal Disorders drug therapy Thromboembolism drug therapy Warfarin therapeutic use 1979 8 4 1979 8 4 0 1 1979 8 4 0 0 ppublish 476455 PMC1595688

1979 British medical journal

180. Pulmonary Embolism in Pregnancy

Pulmonary Embolism in Pregnancy Pulmonary Embolism in Pregnancy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Pulmonary Embolism (...) in Pregnancy Pulmonary Embolism in Pregnancy Aka: Pulmonary Embolism in Pregnancy II. Epidemiology See Two thirds of thromboembolic events in pregnancy are DVT (diagnosable by ) Overall risk of Pulmonary Embolism in Pregnancy: 3 in 10,000 Risk of increases with advancing pregnancy and especially postpartum First trimester : 1 in 50,000 Third trimester : 1 in 10,000 Two thirds of pregnancy-related occur postpartum (esp after ) III. Symptoms and signs See may be present Unilateral leg signs of may be present

2018 FP Notebook

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>